

# Brenda F Kurland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5109587/publications.pdf>

Version: 2024-02-01

111  
papers

6,708  
citations

57631

44  
h-index

64668

79  
g-index

112  
all docs

112  
docs citations

112  
times ranked

9750  
citing authors



#	ARTICLE	IF	CITATIONS
19	Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1210-1211.	2.8	2
20	Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 407-415.	3.2	88
21	Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in <i>KRAS</i> Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 793-804.	1.9	41
22	DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence. <i>Scientific Reports</i> , 2017, 7, 2115.	1.6	20
23	FDG PET and FES PET Predict PFS on Endocrine Therapy Response. <i>Clinical Cancer Research</i> , 2017, 23, 3475-3475.	3.2	0
24	Diffusion-Weighted Breast Magnetic Resonance Imaging. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 428-435.	0.5	16
25	Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 76.	2.2	25
26	Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 402-410.	1.3	25
27	For Health-Related Quality of Life and Other Longitudinal Data, Analysis Should Distinguish Between Truncation by Death and Data Missing Because of Nonresponse. <i>Journal of Clinical Oncology</i> , 2016, 34, 4449-4449.	0.8	4
28	Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in <i>KRAS</i> mutant lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8795-8800.	3.3	14
29	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <i>BRCA</i> Mutation-Associated Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2855-2864.	3.2	80
30	Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. <i>Journal of Nuclear Medicine</i> , 2016, 57, 226-230.	2.8	21
31	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1130-1137.	3.2	166
32	ATM protein is deficient in over 40% of lung adenocarcinomas. <i>Oncotarget</i> , 2016, 7, 57714-57725.	0.8	35
33	Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey. <i>Tomography</i> , 2016, 2, 276-282.	0.8	1
34	Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma. <i>American Journal of Neuroradiology</i> , 2015, 36, 2170-2176.	1.2	41
35	Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles. <i>Scientific Reports</i> , 2015, 5, 15641.	1.6	16
36	Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1538-1545.	0.5	33

#	ARTICLE	IF	CITATIONS
37	External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 236-243.	0.4	34
38	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <i>BRAF</i> mutations in the Lung Cancer Metastasis Consortium. <i>Cancer</i> , 2015, 121, 448-456.	2.0	102
39	Signal enhancement ratio (SER) quantified from breast DCE-MRI and breast cancer risk. <i>Proceedings of SPIE</i> , 2015, , .	0.8	1
40	Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment. <i>Statistical Methods in Medical Research</i> , 2015, 24, 27-67.	0.7	272
41	Effect of 18F-FDG Uptake Time on Lesion Detectability in PET Imaging of Early-Stage Breast Cancer. <i>Tomography</i> , 2015, 1, 53-60.	0.8	12
42	Assessment of Joint and Fascia Manifestations in Chronic Graft-versus-Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052.	2.9	50
43	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344.	2.0	76
44	A Phase 2 Study of $^{18}\text{F}$ -fluoro- $^{17}\beta$ -estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). <i>Molecular Imaging and Biology</i> , 2014, 16, 431-440.	1.3	80
45	ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. <i>British Journal of Cancer</i> , 2013, 109, 2096-2105.	2.9	53
46	Analysis of Gastrointestinal and Hepatic Chronic Graft-versus-Host Disease Manifestations on Major Outcomes: A Chronic Graft-versus-Host Disease Consortium Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 784-791.	2.0	43
47	Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. <i>Bone Marrow Transplantation</i> , 2013, 48, 1123-1128.	1.3	41
48	Multicenter trials using 18F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: Effects of differential measurement error and bias on power calculations for unselected and enrichment designs. <i>Clinical Trials</i> , 2013, 10, 886-895.	0.7	11
49	Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. <i>Leukemia</i> , 2013, 27, 1196-1201.	3.3	21
50	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1415-1421.	0.8	180
51	A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors. <i>PLoS ONE</i> , 2013, 8, e74671.	1.1	25
52	Circulating biomarkers in patients receiving neoadjuvant chemotherapy combined with sunitinib for locally advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1089-1089.	0.8	8
53	A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1090-1090.	0.8	0
54	Accommodation of missing data in supportive and palliative care clinical trials. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 465-470.	0.5	7

#	ARTICLE	IF	CITATIONS
55	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	0.6	101
56	Structural and Molecular Imaging in Cancer Therapy Clinical Trials. , 2012, , 387-412.		0
57	Validation of Measurement Scales in Ocular Graft-versus-Host Disease. <i>Ophthalmology</i> , 2012, 119, 487-493.	2.5	83
58	Quantitative assessment of dynamic PET imaging data in cancer imaging. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1203-1215.	1.0	84
59	Promise and pitfalls of quantitative imaging in oncology clinical trials. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1301-1312.	1.0	83
60	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. <i>EJNMMI Research</i> , 2012, 2, 34.	1.1	27
61	Design Considerations for using PET as a Response Measure in Single Site and Multicenter Clinical Trials. <i>Academic Radiology</i> , 2012, 19, 184-190.	1.3	30
62	Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5503-5503.	0.8	3
63	Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5515-5515.	0.8	5
64	Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS3109-TPS3109.	0.8	0
65	Quantitative measures of FDG PET after neoadjuvant chemotherapy to predict breast cancer patient survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1088-1088.	0.8	0
66	Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. <i>Blood</i> , 2012, 120, 1940-1940.	0.6	0
67	Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium. <i>Blood</i> , 2012, 120, 464-464.	0.6	0
68	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	0.6	319
69	Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. <i>Nuclear Medicine and Biology</i> , 2011, 38, 969-978.	0.3	62
70	Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. <i>Haematologica</i> , 2011, 96, 1528-1535.	1.7	48
71	Probability of malignancy for lesions detected on breast MRI: a predictive model incorporating BI-RADS imaging features and patient characteristics. <i>European Radiology</i> , 2011, 21, 1609-1617.	2.3	26
72	Improved diagnostic accuracy of breast MRI through combined apparent diffusion coefficients and dynamic contrast-enhanced kinetics. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 1759-1767.	1.9	86

#	ARTICLE	IF	CITATIONS
73	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4799-4805.	3.2	120
74	PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake. <i>Clinical Cancer Research</i> , 2011, 17, 2400-2409.	3.2	94
75	Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by <sup>18</sup> F-Fluoroestradiol PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1541-1549.	2.8	65
76	Prospective Neurocognitive Function Over 5 Years After Allogeneic Hematopoietic Cell Transplantation for Cancer Survivors Compared With Matched Controls at 5 Years. <i>Journal of Clinical Oncology</i> , 2011, 29, 2397-2404.	0.8	113
77	Change in NIH Skin Score $\leq 3$ Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium. <i>Blood</i> , 2011, 118, 151-151.	0.6	0
78	Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 562-570.	1.9	148
79	Association between serial dynamic contrast-enhanced MRI and dynamic <sup>18</sup> F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 1124-1131.	1.9	41
80	Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2803-2810.	3.2	72
81	Apparent Diffusion Coefficient Values for Discriminating Benign and Malignant Breast MRI Lesions: Effects of Lesion Type and Size. <i>American Journal of Roentgenology</i> , 2010, 194, 1664-1673.	1.0	145
82	Preoperative and Intraoperative Sonographic Visibility of Collagen-Based Breast Biopsy Marker Clips. <i>Academic Radiology</i> , 2010, 17, 340-347.	1.3	22
83	Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium. <i>Blood</i> , 2010, 116, 393-393.	0.6	0
84	BI-RADS Lesion Characteristics Predict Likelihood of Malignancy in Breast MRI for Masses But Not for Nonmasslike Enhancement. <i>American Journal of Roentgenology</i> , 2009, 193, 994-1000.	1.0	150
85	Quantitative Diffusion-Weighted Imaging as an Adjunct to Conventional Breast MRI for Improved Positive Predictive Value. <i>American Journal of Roentgenology</i> , 2009, 193, 1716-1722.	1.0	246
86	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2009, 30, 1026-1036.	1.5	558
87	Clinical Indication and Patient Age Predict Likelihood of Malignancy in Suspicious Breast MRI Lesions. <i>Academic Radiology</i> , 2009, 16, 1281-1285.	1.3	12
88	Longitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research Aims. <i>Statistical Science</i> , 2009, 24, 211.	1.6	145
89	High Epidermal Growth Factor Receptor Expression in Metastatic Colorectal Cancer Lymph Nodes May Be More Prognostic of Poor Survival Than in Primary Tumor. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 245-252.	0.6	19
90	Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD). <i>Blood</i> , 2009, 114, 2256-2256.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan. <i>Gynecologic Oncology</i> , 2008, 110, 146-151.	0.6	7
92	Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1632-1639.	0.7	96
93	Metabolic and Vascular Features of Dynamic Contrast-enhanced Breast Magnetic Resonance Imaging and 15O-Water Positron Emission Tomography Blood Flow in Breast Cancer. <i>Academic Radiology</i> , 2008, 15, 1246-1254.	1.3	34
94	Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4449-4457.	0.8	142
95	Race/ethnic differences in AD survival in US Alzheimer's Disease Centers. <i>Neurology</i> , 2008, 70, 1163-1170.	1.5	118
96	Education, cognitive function, and severity of neuropathology in Alzheimer disease. <i>Neurology</i> , 2008, 70, 1732-1739.	1.5	91
97	Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. <i>Blood</i> , 2008, 111, 989-996.	0.6	111
98	Dynamic and Static Approaches to Quantifying 18F-FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSF. <i>Journal of Nuclear Medicine</i> , 2007, 48, 920-925.	2.8	61
99	Internal Mammary Nodal Chain Drainage Is a Prognostic Indicator in Axillary Node-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 2985-2993.	0.7	44
100	Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). <i>Breast Cancer Research and Treatment</i> , 2007, 105, 87-94.	1.1	97
101	Longitudinal Change in Positive Affect in Community-Dwelling Older Persons. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1846-1853.	1.3	25
102	Talking and reading science: Longitudinal data on sex differences in mother-child conversations in low-income families. <i>Journal of Applied Developmental Psychology</i> , 2005, 26, 1-19.	0.8	65
103	Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths. <i>Biostatistics</i> , 2005, 6, 241-258.	0.9	108
104	Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out. <i>Statistics in Medicine</i> , 2004, 23, 2673-2695.	0.8	22
105	The Burden and Patterns of Disability in Activities of Daily Living Among Community-living Older Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, M70-M75.	1.7	123
106	Prognostic Effect of Prior Disability Episodes among Nondisabled Community-living Older Persons. <i>American Journal of Epidemiology</i> , 2003, 158, 1090-1096.	1.6	51
107	A 3-dimensional analysis of molar movement during headgear treatment. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2002, 121, 18-29.	0.8	95
108	Misspecified maximum likelihood estimates and generalised linear mixed models. <i>Biometrika</i> , 2001, 88, 973-985.	1.3	234

#	ARTICLE	IF	CITATIONS
109	Dinner talk: Cultural patterns of sociability and socialization in family discourse. Shoshana Blum-Kulka. Mahwah, NJ: Erlbaum, 1997. PP. 306.. Applied Psycholinguistics, 1998, 19, 519-523.	0.8	0
110	Longitudinal measurement of growth in definitional skill. Journal of Child Language, 1997, 24, 603-625.	0.8	35
111	SHELL: Oral Language and Early Literacy Skills in Kindergarten and First-Grade Children. Journal of Research in Childhood Education, 1995, 10, 37-48.	0.6	171